Canaccord raised the firm’s price target on Globus Medical (GMED) to $101 from $92 and keeps a Buy rating on the shares. The firm updated its model following the company’s preannouncement where they reported strong preliminary results, announcing 2025 revenue guidance with the midpoint calling for 6.2% growth, which Canaccord views as conservative.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical upgraded to Neutral from Underperform at BofA
- Closing Bell Movers: Penguin Solutions up 16% on earnings beat
- Globus Medical sees Q4 revenue $657M, consensus $635.46M
- Globus Medical raises FY24 revenue view to $2.52B from $2.49B-$2.5B
- Globus Medical sees FY25 EPS $3.40-$3.50, consensus $3.42